BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kultti A, Zhao C, Singha NC, Zimmerman S, Osgood RJ, Symons R, Jiang P, Li X, Thompson CB, Infante JR. Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironment. Biomed Res Int. 2014;2014:817613. [PMID: 25147816 DOI: 10.1155/2014/817613] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Kohi S, Sato N, Cheng X, Koga A, Hirata K. Increased Expression of HYAL1 in Pancreatic Ductal Adenocarcinoma. Pancreas 2016;45:1467-73. [DOI: 10.1097/mpa.0000000000000670] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Zhao C, Thompson BJ, Chen K, Gao F, Blouw B, Marella M, Zimmerman S, Kimbler T, Garrovillo S, Bahn J, Huang L, Huang Z, Shepard HM, Rosengren S, Thanos CD, Maneval DC. The growth of a xenograft breast cancer tumor model with engineered hyaluronan-accumulating stroma is dependent on hyaluronan and independent of CD44. Oncotarget 2019;10:6561-76. [PMID: 31762938 DOI: 10.18632/oncotarget.27302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Nguyen N, Kumar A, Chacko S, Ouellette RJ, Ghosh A. Human hyaluronic acid synthase-1 promotes malignant transformation via epithelial-to-mesenchymal transition, micronucleation and centrosome abnormalities. Cell Commun Signal 2017;15:48. [PMID: 29137675 DOI: 10.1186/s12964-017-0204-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
4 Heineman T, Baumgart M, Nanavati C, Gabrail N, Van Wart SA, Mager DE, Maneval DC, Fathallah AM, Sekulovich RE. Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non-small cell lung cancer. Clin Transl Sci 2021. [PMID: 33982408 DOI: 10.1111/cts.13041] [Reference Citation Analysis]
5 Wang HC, Lin YL, Hsu CC, Chao YJ, Hou YC, Chiu TJ, Huang PH, Tang MJ, Chen LT, Shan YS. Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8. Theranostics 2019;9:7168-83. [PMID: 31695760 DOI: 10.7150/thno.36830] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
6 Tesfaye AA, Kamgar M, Azmi A, Philip PA. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Rev Anticancer Ther. 2018;18:131-148. [PMID: 29254387 DOI: 10.1080/14737140.2018.1417844] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
7 Nykopp TK, Pasonen-seppänen S, Tammi MI, Tammi RH, Kosma V, Anttila M, Sironen R. Decreased hyaluronidase 1 expression is associated with early disease recurrence in human endometrial cancer. Gynecologic Oncology 2015;137:152-9. [DOI: 10.1016/j.ygyno.2015.01.525] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
8 Houg DS, Bijlsma MF. The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma. Mol Cancer. 2018;17:95. [PMID: 29903049 DOI: 10.1186/s12943-018-0842-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
9 Shepard HM. Breaching the Castle Walls: Hyaluronan Depletion as a Therapeutic Approach to Cancer Therapy. Front Oncol. 2015;5:192. [PMID: 26380222 DOI: 10.3389/fonc.2015.00192] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 6.1] [Reference Citation Analysis]
10 Barnes J, Dweik RA. Is pulmonary hypertension a metabolic disease? Am J Respir Crit Care Med 2014;190:973-5. [PMID: 25360726 DOI: 10.1164/rccm.201409-1702ED] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
11 Alibardi L. Hyaluronic acid in the tail and limb of amphibians and lizards recreates permissive embryonic conditions for regeneration due to its hygroscopic and immunosuppressive properties. J Exp Zool (Mol Dev Evol ) 2017;328:760-71. [DOI: 10.1002/jez.b.22771] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
12 Alibardi L. Hyaluronate likely contributes to the immunesuppression of the regenerating tail blastema in lizards: Implications for organ regeneration in amniotes. Acta Zool 2018;99:321-30. [DOI: 10.1111/azo.12214] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Maksimenko AV. Widening and Elaboration of Consecutive Research into Therapeutic Antioxidant Enzyme Derivatives. Oxid Med Cell Longev 2016;2016:3075695. [PMID: 27148430 DOI: 10.1155/2016/3075695] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
14 Deen AJ, Arasu UT, Pasonen-Seppänen S, Hassinen A, Takabe P, Wojciechowski S, Kärnä R, Rilla K, Kellokumpu S, Tammi R, Tammi M, Oikari S. UDP-sugar substrates of HAS3 regulate its O-GlcNAcylation, intracellular traffic, extracellular shedding and correlate with melanoma progression. Cell Mol Life Sci 2016;73:3183-204. [PMID: 26883802 DOI: 10.1007/s00018-016-2158-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
15 Hessmann E, Buchholz SM, Demir IE, Singh SK, Gress TM, Ellenrieder V, Neesse A. Microenvironmental Determinants of Pancreatic Cancer. Physiological Reviews 2020;100:1707-51. [DOI: 10.1152/physrev.00042.2019] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
16 Mehta A, Hwang WL, Weekes C. The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma. Ann Pancreat Cancer 2020;3:3. [PMID: 33294843 DOI: 10.21037/apc-2020-pda-05] [Reference Citation Analysis]
17 Cheng XB, Kohi S, Koga A, Hirata K, Sato N. Hyaluronan stimulates pancreatic cancer cell motility. Oncotarget. 2016;7:4829-4840. [PMID: 26684359 DOI: 10.18632/oncotarget.6617] [Cited by in Crossref: 39] [Cited by in F6Publishing: 46] [Article Influence: 6.5] [Reference Citation Analysis]
18 Li X, Li J, Zhang B, Gu Y, Li Q, Gu G, Xiong J, Li Y, Yang X, Qian Z. Comparative peptidome profiling reveals critical roles for peptides in the pathology of pancreatic cancer. Int J Biochem Cell Biol 2020;120:105687. [PMID: 31927104 DOI: 10.1016/j.biocel.2020.105687] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
19 Liang C, Shi S, Meng Q, Liang D, Ji S, Zhang B, Qin Y, Xu J, Ni Q, Yu X. Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going. Exp Mol Med 2017;49:e406. [PMID: 29611542 DOI: 10.1038/emm.2017.255] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 10.4] [Reference Citation Analysis]
20 Takabe P, Bart G, Ropponen A, Rilla K, Tammi M, Tammi R, Pasonen-Seppänen S. Hyaluronan synthase 3 (HAS3) overexpression downregulates MV3 melanoma cell proliferation, migration and adhesion. Exp Cell Res 2015;337:1-15. [PMID: 26222208 DOI: 10.1016/j.yexcr.2015.07.026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
21 Karousou E, Misra S, Ghatak S, Dobra K, Götte M, Vigetti D, Passi A, Karamanos NK, Skandalis SS. Roles and targeting of the HAS/hyaluronan/CD44 molecular system in cancer. Matrix Biol 2017;59:3-22. [PMID: 27746219 DOI: 10.1016/j.matbio.2016.10.001] [Cited by in Crossref: 94] [Cited by in F6Publishing: 95] [Article Influence: 15.7] [Reference Citation Analysis]
22 Amorim S, Soares da Costa D, Mereiter S, Pashkuleva I, Reis CA, Reis RL, Pires RA. Multilayer platform to model the bioactivity of hyaluronic acid in gastric cancer. Mater Sci Eng C Mater Biol Appl 2021;119:111616. [PMID: 33321659 DOI: 10.1016/j.msec.2020.111616] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Gagliano N, Sforza C, Sommariva M, Menon A, Conte V, Sartori P, Procacci P. 3D-spheroids: What can they tell us about pancreatic ductal adenocarcinoma cell phenotype? Exp Cell Res 2017;357:299-309. [PMID: 28571915 DOI: 10.1016/j.yexcr.2017.05.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
24 Larson BK, Guan M, Placencio V, Tuli R, Hendifar AE. Stromal hyaluronan accumulation is associated with low tumor grade and nodal metastases in pancreatic ductal adenocarcinoma. Hum Pathol 2019;90:37-44. [PMID: 31121193 DOI: 10.1016/j.humpath.2019.05.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Sánchez N, González-Ramírez MC, Contreras EG, Ubilla A, Li J, Valencia A, Wilson A, Green JBA, Tucker AS, Gaete M. Balance Between Tooth Size and Tooth Number Is Controlled by Hyaluronan. Front Physiol 2020;11:996. [PMID: 32982773 DOI: 10.3389/fphys.2020.00996] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Arasu UT, Deen AJ, Pasonen-Seppänen S, Heikkinen S, Lalowski M, Kärnä R, Härkönen K, Mäkinen P, Lázaro-Ibáñez E, Siljander PR, Oikari S, Levonen AL, Rilla K. HAS3-induced extracellular vesicles from melanoma cells stimulate IHH mediated c-Myc upregulation via the hedgehog signaling pathway in target cells. Cell Mol Life Sci 2020;77:4093-115. [PMID: 31820036 DOI: 10.1007/s00018-019-03399-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
27 Compagnone M, Gatti V, Presutti D, Ruberti G, Fierro C, Markert EK, Vousden KH, Zhou H, Mauriello A, Anemone L, Bongiorno-Borbone L, Melino G, Peschiaroli A. ΔNp63-mediated regulation of hyaluronic acid metabolism and signaling supports HNSCC tumorigenesis. Proc Natl Acad Sci U S A 2017;114:13254-9. [PMID: 29162693 DOI: 10.1073/pnas.1711777114] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
28 Veenstra VL, Garcia-Garijo A, van Laarhoven HW, Bijlsma MF. Extracellular Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer. Cancers (Basel) 2018;10:E34. [PMID: 29382042 DOI: 10.3390/cancers10020034] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
29 Pitarresi JR, Liu X, Avendano A, Thies KA, Sizemore GM, Hammer AM, Hildreth BE 3rd, Wang DJ, Steck SA, Donohue S, Cuitiño MC, Kladney RD, Mace TA, Chang JJ, Ennis CS, Li H, Reeves RH, Blackshaw S, Zhang J, Yu L, Fernandez SA, Frankel WL, Bloomston M, Rosol TJ, Lesinski GB, Konieczny SF, Guttridge DC, Rustgi AK, Leone G, Song JW, Wu J, Ostrowski MC. Disruption of stromal hedgehog signaling initiates RNF5-mediated proteasomal degradation of PTEN and accelerates pancreatic tumor growth. Life Sci Alliance 2018;1:e201800190. [PMID: 30456390 DOI: 10.26508/lsa.201800190] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
30 Kohi S, Sato N, Cheng XB, Koga A, Higure A, Hirata K. A novel epigenetic mechanism regulating hyaluronan production in pancreatic cancer cells. Clin Exp Metastasis 2016;33:225-30. [PMID: 26589701 DOI: 10.1007/s10585-015-9771-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
31 Neesse A, Algül H, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut. 2015;64:1476-1484. [PMID: 25994217 DOI: 10.1136/gutjnl-2015-309304] [Cited by in Crossref: 281] [Cited by in F6Publishing: 275] [Article Influence: 40.1] [Reference Citation Analysis]
32 Aldea M, Florian IA, Kacso G, Craciun L, Boca S, Soritau O, Florian IS. Nanoparticles for Targeting Intratumoral Hypoxia: Exploiting a Potential Weakness of Glioblastoma. Pharm Res 2016;33:2059-77. [DOI: 10.1007/s11095-016-1947-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
33 Wang Z, Zhao K, Hackert T, Zöller M. CD44/CD44v6 a Reliable Companion in Cancer-Initiating Cell Maintenance and Tumor Progression. Front Cell Dev Biol 2018;6:97. [PMID: 30211160 DOI: 10.3389/fcell.2018.00097] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 10.8] [Reference Citation Analysis]
34 MacCurtain BM, Quirke NP, Thorpe SD, Gallagher TK. Pancreatic Ductal Adenocarcinoma: Relating Biomechanics and Prognosis. J Clin Med 2021;10:2711. [PMID: 34205335 DOI: 10.3390/jcm10122711] [Reference Citation Analysis]
35 Tammi MI, Oikari S, Pasonen-seppänen S, Rilla K, Auvinen P, Tammi RH. Activated hyaluronan metabolism in the tumor matrix — Causes and consequences. Matrix Biology 2019;78-79:147-64. [DOI: 10.1016/j.matbio.2018.04.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
36 Kurniawan NA, Chaudhuri PK, Lim CT. Mechanobiology of cell migration in the context of dynamic two-way cell-matrix interactions. J Biomech 2016;49:1355-68. [PMID: 26747513 DOI: 10.1016/j.jbiomech.2015.12.023] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
37 Carvalho TMA, Di Molfetta D, Greco MR, Koltai T, Alfarouk KO, Reshkin SJ, Cardone RA. Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as Therapeutic Approaches. Cancers (Basel) 2021;13:6135. [PMID: 34885243 DOI: 10.3390/cancers13236135] [Reference Citation Analysis]
38 Chang IW, Liang PI, Li CC, Wu WJ, Huang CN, Lin VC, Hsu CT, He HL, Wu TF, Hung CH, Li CF. HAS3 underexpression as an indicator of poor prognosis in patients with urothelial carcinoma of the upper urinary tract and urinary bladder. Tumour Biol 2015;36:5441-50. [PMID: 25934334 DOI: 10.1007/s13277-015-3210-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
39 Sato N, Kohi S, Hirata K, Goggins M. Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight. Cancer Sci. 2016;107:569-575. [PMID: 26918382 DOI: 10.1111/cas.12913] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 9.7] [Reference Citation Analysis]
40 Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, Hitre E, Hammel P, Hendifar AE, Bates SE, Li CP, Hingorani SR, de la Fouchardiere C, Kasi A, Heinemann V, Maraveyas A, Bahary N, Layos L, Sahai V, Zheng L, Lacy J, Park JO, Portales F, Oberstein P, Wu W, Chondros D, Bullock AJ; HALO 109-301 Investigators. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol 2020;38:3185-94. [PMID: 32706635 DOI: 10.1200/JCO.20.00590] [Cited by in Crossref: 50] [Cited by in F6Publishing: 31] [Article Influence: 25.0] [Reference Citation Analysis]
41 Li X, Shepard HM, Cowell JA, Zhao C, Osgood RJ, Rosengren S, Blouw B, Garrovillo SA, Pagel MD, Whatcott CJ, Han H, Von Hoff DD, Taverna DM, LaBarre MJ, Maneval DC, Thompson CB. Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression. Clin Cancer Res 2018;24:4798-807. [PMID: 30084839 DOI: 10.1158/1078-0432.CCR-17-3284] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
42 Gatti V, Fierro C, Compagnone M, Giangrazi F, Markert EK, Bongiorno-Borbone L, Melino G, Peschiaroli A. ΔNp63 regulates the expression of hyaluronic acid-related genes in breast cancer cells. Oncogenesis 2018;7:65. [PMID: 30139970 DOI: 10.1038/s41389-018-0073-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
43 Venning FA, Wullkopf L, Erler JT. Targeting ECM Disrupts Cancer Progression. Front Oncol 2015;5:224. [PMID: 26539408 DOI: 10.3389/fonc.2015.00224] [Cited by in Crossref: 141] [Cited by in F6Publishing: 138] [Article Influence: 20.1] [Reference Citation Analysis]
44 Malik R, Lelkes PI, Cukierman E. Biomechanical and biochemical remodeling of stromal extracellular matrix in cancer. Trends Biotechnol. 2015;33:230-236. [PMID: 25708906 DOI: 10.1016/j.tibtech.2015.01.004] [Cited by in Crossref: 163] [Cited by in F6Publishing: 160] [Article Influence: 23.3] [Reference Citation Analysis]
45 Vennin C, Herrmann D, Lucas MC, Timpson P. Intravital imaging reveals new ancillary mechanisms co-opted by cancer cells to drive tumor progression. F1000Res 2016;5:F1000 Faculty Rev-892. [PMID: 27239290 DOI: 10.12688/f1000research.8090.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
46 Hu X, Xia F, Lee J, Li F, Lu X, Zhuo X, Nie G, Ling D. Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma. Adv Sci (Weinh) 2021;8:2002545. [PMID: 33854877 DOI: 10.1002/advs.202002545] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
47 Looi CK, Chung FF, Leong CO, Wong SF, Rosli R, Mai CW. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. J Exp Clin Cancer Res. 2019;38:162. [PMID: 30987642 DOI: 10.1186/s13046-019-1153-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 14.7] [Reference Citation Analysis]
48 Saluja AK, Dudeja V, Banerjee S. Evolution of novel therapeutic options for pancreatic cancer. Curr Opin Gastroenterol 2016;32:401-7. [PMID: 27454027 DOI: 10.1097/MOG.0000000000000298] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
49 Rankin KS, Frankel D. Hyaluronan in cancer - from the naked mole rat to nanoparticle therapy. Soft Matter 2016;12:3841-8. [PMID: 27079782 DOI: 10.1039/c6sm00513f] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
50 Pedron S, Hanselman JS, Schroeder MA, Sarkaria JN, Harley BAC. Extracellular Hyaluronic Acid Influences the Efficacy of EGFR Tyrosine Kinase Inhibitors in a Biomaterial Model of Glioblastoma. Adv Healthc Mater 2017;6. [PMID: 28766870 DOI: 10.1002/adhm.201700529] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
51 Kuo YZ, Fang WY, Huang CC, Tsai ST, Wang YC, Yang CL, Wu LW. Hyaluronan synthase 3 mediated oncogenic action through forming inter-regulation loop with tumor necrosis factor alpha in oral cancer. Oncotarget 2017;8:15563-83. [PMID: 28107185 DOI: 10.18632/oncotarget.14697] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
52 Spinelli FM, Vitale DL, Sevic I, Alaniz L. Hyaluronan in the Tumor Microenvironment. Adv Exp Med Biol 2020;1245:67-83. [PMID: 32266653 DOI: 10.1007/978-3-030-40146-7_3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
53 Wu R, Huang L, Zhao H, Geng X. Hyaluronic acid in digestive cancers. J Cancer Res Clin Oncol 2017;143:1-16. [DOI: 10.1007/s00432-016-2213-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
54 Edwards P, Kang BW, Chau I. Targeting the Stroma in the Management of Pancreatic Cancer. Front Oncol 2021;11:691185. [PMID: 34336679 DOI: 10.3389/fonc.2021.691185] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Kanat O, Ertas H. Shattering the castle walls: Anti-stromal therapy for pancreatic cancer. World J Gastrointest Oncol 2018; 10(8): 202-210 [PMID: 30147846 DOI: 10.4251/wjgo.v10.i8.202] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
56 Caon I, Bartolini B, Parnigoni A, Caravà E, Moretto P, Viola M, Karousou E, Vigetti D, Passi A. Revisiting the hallmarks of cancer: The role of hyaluronan. Semin Cancer Biol 2020;62:9-19. [PMID: 31319162 DOI: 10.1016/j.semcancer.2019.07.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 10.7] [Reference Citation Analysis]
57 Morosi L, Meroni M, Ubezio P, Fuso Nerini I, Minoli L, Porcu L, Panini N, Colombo M, Blouw B, Kang DW, Davoli E, Zucchetti M, D'Incalci M, Frapolli R. PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models. J Exp Clin Cancer Res 2021;40:286. [PMID: 34507591 DOI: 10.1186/s13046-021-02070-x] [Reference Citation Analysis]
58 Heeg S, Das KK, Reichert M, Bakir B, Takano S, Caspers J, Aiello NM, Wu K, Neesse A, Maitra A, Iacobuzio-Donahue CA, Hicks P, Rustgi AK. ETS-Transcription Factor ETV1 Regulates Stromal Expansion and Metastasis in Pancreatic Cancer. Gastroenterology 2016;151:540-553.e14. [PMID: 27318148 DOI: 10.1053/j.gastro.2016.06.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
59 Qiu W, Chen R, Chen X, Zhang H, Song L, Cui W, Zhang J, Ye D, Zhang Y, Wang Z. Oridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer. Int J Nanomedicine 2018;13:6809-27. [PMID: 30425490 DOI: 10.2147/IJN.S177993] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
60 Christenson ES, Jaffee E, Azad NS. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. Lancet Oncol. 2020;21:e135-e145. [PMID: 32135117 DOI: 10.1016/s1470-2045(19)30795-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 20.5] [Reference Citation Analysis]
61 Chanmee T, Ontong P, Itano N. Hyaluronan: A modulator of the tumor microenvironment. Cancer Letters 2016;375:20-30. [DOI: 10.1016/j.canlet.2016.02.031] [Cited by in Crossref: 116] [Cited by in F6Publishing: 114] [Article Influence: 19.3] [Reference Citation Analysis]
62 Sato N, Cheng XB, Kohi S, Koga A, Hirata K. Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma. Acta Pharm Sin B 2016;6:101-5. [PMID: 27006892 DOI: 10.1016/j.apsb.2016.01.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
63 Placencio-Hickok VR, Lauzon M, Moshayedi N, Guan M, Kim S, Nissen N, Lo S, Pandol S, Larson BK, Gong J, Hendifar AE, Osipov A. Hyaluronan heterogeneity in pancreatic ductal adenocarcinoma: Primary tumors compared to sites of metastasis. Pancreatology 2021:S1424-3903(21)00579-2. [PMID: 34657790 DOI: 10.1016/j.pan.2021.09.015] [Reference Citation Analysis]
64 Gatti V, Fierro C, Annicchiarico-Petruzzelli M, Melino G, Peschiaroli A. ΔNp63 in squamous cell carcinoma: defining the oncogenic routes affecting epigenetic landscape and tumour microenvironment. Mol Oncol 2019;13:981-1001. [PMID: 30845357 DOI: 10.1002/1878-0261.12473] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
65 Koltai T, Reshkin SJ, Carvalho TMA, Cardone RA. Targeting the Stromal Pro-Tumoral Hyaluronan-CD44 Pathway in Pancreatic Cancer. Int J Mol Sci 2021;22:3953. [PMID: 33921242 DOI: 10.3390/ijms22083953] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Passi A, Vigetti D, Buraschi S, Iozzo RV. Dissecting the role of hyaluronan synthases in the tumor microenvironment. FEBS J 2019;286:2937-49. [PMID: 30974514 DOI: 10.1111/febs.14847] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 11.0] [Reference Citation Analysis]
67 Seufferlein T, Ducreux M, Hidalgo M, Prager G, Cutsem EV. More than a Gel & Hyaluronic Acid, a Central Component in the Microenvironment of Pancreatic Cancer. European Oncology & Haematology 2018;14:40. [DOI: 10.17925/eoh.2018.14.1.40] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
68 Infante JR, Korn RL, Rosen LS, LoRusso P, Dychter SS, Zhu J, Maneval DC, Jiang P, Shepard HM, Frost G, Von Hoff DD, Borad MJ, Ramanathan RK. Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours. Br J Cancer 2018;118:153-61. [PMID: 28949957 DOI: 10.1038/bjc.2017.327] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
69 Wang S, Zhen L, Liu Z, Ai Q, Ji Y, Du G, Wang Y, Bu Y. Identification and analysis of the promoter region of the human HAS3 gene. Biochem Biophys Res Commun 2015;460:1008-14. [PMID: 25843802 DOI: 10.1016/j.bbrc.2015.03.142] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
70 Coppola S, Carnevale I, Danen EHJ, Peters GJ, Schmidt T, Assaraf YG, Giovannetti E. A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer. Drug Resist Updat 2017;31:43-51. [PMID: 28867243 DOI: 10.1016/j.drup.2017.07.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
71 Scodeller P. Extracellular Matrix Degrading Enzymes for Nanocarrier-Based Anticancer Therapy. In: Prokop A, Weissig V, editors. Intracellular Delivery III. Cham: Springer International Publishing; 2016. pp. 49-66. [DOI: 10.1007/978-3-319-43525-1_3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]